Jobs
-
Inhaled drug developer Alexza Pharmaceuticals has signed a non-binding letter of intent and entered into discussions with Grupo Ferrer regarding Ferrer’s acquisition offer, the company said. Alexza noted that the letter of intent allows the… Read more . . .
-
MannKind Corporation has announced the death of founder and Chairman Emeritus Alfred Mann at age 90, one week after he stepped down as Chairman of the Board. Mann served as CEO from November 2003 until… Read more . . .
-
Norwegian CDMO Curida, which offers a wide range of analytical, development, and manufacturing services for OINDPs, has announced a new strategic partnership with pharmAccel Consulting Director René Bommer. In July 2015, Curida acquired a nasal… Read more . . .
-
Adapt Pharma has announced the availability of Narcan naloxone hydrochloride nasal spray for the treatment of opioid overdose in the US. Narcan nasal spray was approved by the FDA in November 2015. In 17 of… Read more . . .
-
Health Canada has approved Teva Canada Limited’s application for its tobramycin inhalation solution, a generic version of Novartis’s TOBI inhalation solution for the treatment of P. aeruginosa infections in cystic fibrosis patients in Canada. The… Read more . . .
-
Propeller Health and Aptar Pharma have teamed up to develop a connected MDI that features an integrated sensor and an electronic dose counter. The companies say that they expect to begin clinical studies with the… Read more . . .
-
Laboratory automation company Astech Projects has been acquired by German holding company the Schauenburg International Group. Astech Projects manufactures the Xelair, Xelize, and Xelox ranges of automated inhaler testing systems and offers systems for nasal… Read more . . .
-
The FDA published notices on February 16, 2016 announcing publication of draft guidances titled “Allergic Rhinitis: Developing Drug Products for Treatment” and “Nonallergic Rhinitis: Developing Drug Products for Treatment. The agency says that comments should… Read more . . .
-
Lannett Company has received FDA approval for its sumatriptan nasal spray, a generic version of GSK’s Imitrex nasal spray. The company cites IMS statistics showing that US sales of sumatriptan nasal spray totaled $62 million… Read more . . .
-
The FDA has accepted Mylan’s abbreviated new drug application for its generic fluticasone propionate/salmeterol DPI and has set a GDUFA goal date of March 28, 2017, the company said. Mylan filed the ANDA for the… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden